These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 10946422)

  • 21. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Anti HCV drugs--ribavirin, telaprevir].
    Sakamoto M; Enomoto N
    Nihon Rinsho; 2012 Apr; 70(4):614-9. PubMed ID: 22568142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.
    Neumann AU; Lam NP; Dahari H; Davidian M; Wiley TE; Mika BP; Perelson AS; Layden TJ
    J Infect Dis; 2000 Jul; 182(1):28-35. PubMed ID: 10882578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Practical evaluation of a mouse with chimeric human liver model for hepatitis C virus infection using an NS3-4A protease inhibitor.
    Kamiya N; Iwao E; Hiraga N; Tsuge M; Imamura M; Takahashi S; Miyoshi S; Tateno C; Yoshizato K; Chayama K
    J Gen Virol; 2010 Jul; 91(Pt 7):1668-77. PubMed ID: 20164258
    [TBL] [Abstract][Full Text] [Related]  

  • 25. First phase viral kinetic parameters as predictors of treatment response and their influence on the second phase viral decline.
    Layden JE; Layden TJ; Reddy KR; Levy-Drummer RS; Poulakos J; Neumann AU
    J Viral Hepat; 2002 Sep; 9(5):340-5. PubMed ID: 12225328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C viral dynamics.
    Layden TJ; Lam NP; Wiley TE
    Clin Liver Dis; 1999 Nov; 3(4):793-810. PubMed ID: 11291251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Triphasic decline of hepatitis C virus RNA during antiviral therapy.
    Dahari H; Ribeiro RM; Perelson AS
    Hepatology; 2007 Jul; 46(1):16-21. PubMed ID: 17596864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antiviral resistance and the future landscape of hepatitis C virus infection therapy.
    Wyles DL
    J Infect Dis; 2013 Mar; 207 Suppl 1():S33-9. PubMed ID: 23390303
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The kinetics of hepatitis C virus infection.
    Zeuzem S
    Clin Liver Dis; 2001 Nov; 5(4):917-30. PubMed ID: 11685801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of bovine viral diarrhea virus in vitro by xanthohumol: comparisons with ribavirin and interferon-alpha and implications for the development of anti-hepatitis C virus agents.
    Zhang N; Liu Z; Han Q; Chen J; Lou S; Qiu J; Zhang G
    Eur J Pharm Sci; 2009 Nov; 38(4):332-40. PubMed ID: 19720145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Interferon].
    Tamori A; Kawada N
    Nihon Rinsho; 2012 Apr; 70(4):620-4. PubMed ID: 22568143
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.
    Banerjee S; Keval R; Gakkhar S
    Math Biosci; 2013 Oct; 245(2):235-48. PubMed ID: 23891586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Analysis on the decline of hepatitis C virus RNA in the blood using a mathematical model].
    Yu ZJ; Kan QC; He Y; Jiang HQ; Liang HX; Li TS
    Zhonghua Gan Zang Bing Za Zhi; 2007 Dec; 15(12):886-8. PubMed ID: 18171519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Will direct-acting antivirals make a difference in HIV-HCV coinfected patients?
    Bruno R; Fagiuoli S; Sacchi P
    Expert Rev Anti Infect Ther; 2011 Sep; 9(9):699-701. PubMed ID: 21905777
    [No Abstract]   [Full Text] [Related]  

  • 35. Viral kinetics and mathematical models.
    Perelson AS
    Am J Med; 1999 Dec; 107(6B):49S-52S. PubMed ID: 10653457
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa.
    Lam NP; Neumann AU; Gretch DR; Wiley TE; Perelson AS; Layden TJ
    Hepatology; 1997 Jul; 26(1):226-31. PubMed ID: 9214474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.
    Rong L; Perelson AS
    Crit Rev Immunol; 2010; 30(2):131-48. PubMed ID: 20370626
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
    Neumann AU; Lam NP; Dahari H; Gretch DR; Wiley TE; Layden TJ; Perelson AS
    Science; 1998 Oct; 282(5386):103-7. PubMed ID: 9756471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Genomic changes in the E2/NS1 region of HCV before and after IFN therapy].
    Higashi Y; Kakumu S
    Nihon Rinsho; 1995 Sep; 53 Suppl(Pt 1):923-9. PubMed ID: 7563902
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    DebRoy S; Hiraga N; Imamura M; Hayes CN; Akamatsu S; Canini L; Perelson AS; Pohl RT; Persiani S; Uprichard SL; Tateno C; Dahari H; Chayama K
    J Viral Hepat; 2016 Sep; 23(9):708-17. PubMed ID: 27272497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.